Steroids for pneumonia in adults in Kenya (SONIA Trial).

Conditions

Community acquired pneumonia Respiratory

Lucinde RK, Gathuri H, Mwaniki P, Orindi B, Otieno EO, Mwakio S, Mulemi L, Isaaka L, Shangala J, Saisi M, Isinde E, Oginga IN, Wachira AW, Manuthu E, Kariuki H, Asaava P, Nyikuli J, Wekesa C, Otedo A, Bosire H, Okoth SB, Ongalo W, Mukabi DM, Lusamba W, Muthui B, Adembesa I, Mithi C, Sood M, Aliyan NA, Gituma B, Matiko MG, Omondi CA, Ombajo LA, Kirui N, Ochola L, Abdi AI, Kagucia EW, English M, Hamaluba M, Ochola-Oyier I, Kamuya D, Bejon P, Barasa E, Agweyu A, Akech S, Etyang AO.

2025-10-291 citations

10.1056/nejmoa2507100

A pragmatic randomized controlled trial of standard care versus corticosteroids plus standard care for treatment of pneumonia in adults admitted to Kenyan hospitals (SONIA).

Lucinde R, Abdi A, Orindi B, Mwakio S, Gathuri H, Onyango E, Chira S, Ogero M, Isaaka L, Shangala J, Oginga IN, Wachira A, Manuthu E, Kariuki H, Nyikuli J, Wekesa C, Otedo A, Bosire H, Okoth SB, Ongalo W, Mukabi D, Lusamba W, Muthui B, Kirui N, Adembesa I, Mithi C, Sood M, Ahmed N, Gituma B, Ongaki VB, Giabe M, Omondi C, Ombajo LA, Kagucia W, English M, Hamaluba M, Ochola-Oyier LI, Kamuya D, Bejon P, Agweyu A, Akech S, Etyang AO.

2022-01-011 citations

10.12688/wellcomeopenres.18401.2

Interventions

Steroid plus standard pneumonia treatment

standard treatment for pneumonia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Adults aged 18 years or over 2.Admitted to hospital with a diagnosis of community-acquired pneumonia. Pneumonia will be based on a clinical definition as follows: the presence of at least 2 of the following signs and symptoms for less than 14 days: cough, fever, dyspnoea, haemoptysis, chest pain or crackles on chest examination. 3.Admitted to hospital within the previous 48 hours 4.Provides written informed consent

Exclusion criteria

Exclusion criteria: 1.Hospital acquired pneumonia- defined as pneumonia in a patient who has been in hospital for >48 hours who did not have the symptoms at admission 2.Patients who in the opinion of the attending clinician, require to be treated with steroids. 3.Known or suspected condition which in the opinion of attending clinician requires treatment with steroids, including but not limited to chronic obstructive pulmonary disease, asthma, adrenal insufficiency, Pneumocystis Jirovecii pneumonia (PCP). 4.If the clinician strongly suspects COVID-19 and wants to provide steroids to the patient because of this suspicion, then the patient will be excluded from the trial. 5.Pregnancy or breast feeding 6.Any contraindication to steroid administration 7.Diagnosis of COVID-19 confirmed via PCR of NP/OP swabs (this only applies if test result known at the point of enrollment)

Design outcomes

Primary

Measure	Time frame
The primary outcome for the trial will be mortality at 30 days after randomization	—

Secondary

Measure	Time frame
1.Mortality at 7,14 and 21 days following randomization 2.In-hospital mortality 3.Mortality after discharge from hospital (up to 30 days post randomization) 4.Duration of hospital stay 5.Admission to ICU/referral to higher level hospital	—

Countries

Kenya

Contacts

Public ContactStella Mwakio

Project coordinator

smwakio@kemri-wellcome.org254724832853

Outcome results

None listed